New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres
作者:Mohamed I. Attia、Wagdy M. Eldehna、Samar A. Afifi、Adam B. Keeton、Gary A. Piazza、Hatem A. Abdel-Aziz
DOI:10.1371/journal.pone.0181241
日期:——
The synthesis and molecular characterization of new isatin-based hydrazonoindolin-2-ones 4a-o and 7a-e are reported. The in vitro anti-proliferative potential of the synthesized compounds 4a-o and 7a-e was examined against HT-29 (colon), ZR-75 (breast) and A549 (lung) human cancer cell lines. Compounds 7b, 7d and 7e were the most active congeners against the tested human cancer cell lines with average IC50 values of 4.77, 3.39 and 2.37 μM, respectively, as compared with the reference isatin-based drug, sunitinib, which exhibited an average IC50 value of 8.11 μM. Compound 7e was selected for further pharmacological evaluation in order to gain insight into its possible mechanism of action. It increased caspase 3/7 activity by 2.4- and 1.85-fold between 4 and 8 h of treatment, respectively, at 10 μM and it caused a decrease in the percentage of cells in the G1 phase of the cell cycle with a corresponding increase in the S-phase. In addition, compound 7e increased phosphorylated tyrosine (p-Tyr) levels nearly two-fold with an apparent IC50 value of 3.8 μM. The 7e-loaded PLGA microspheres were prepared using a modified emulsion-solvent diffusion method. The average encapsulation efficiency of the 7e-loaded PLGA microspheres was 85% ± 1.3. While, the in vitro release profile of the 7e-loaded microspheres was characterized by slow and continuous release of compound 7e during 21 days and the release curve was fitted to zero order kinetics. Incorporation of 7e into PLGA microspheres improved its in vitro anti-proliferative activity toward the human cancer cell line A549 after 120 h incubation period with an IC50 value less than 0.8 μM.
报道了新型靛红酸苯腙基吲哚啉-2-酮类化合物4a-o和7a-e的合成与分子特性研究。对合成的化合物4a-o和7a-e进行了体外抗增殖潜力测试,针对HT-29(结肠)、ZR-75(乳腺)和A549(肺)人类癌细胞系。与参考药物舒尼替尼相比,化合物7b、7d和7e在测试的人类癌细胞系中显示出最高的活性,其平均IC50值分别为4.77、3.39和2.37 μM,而舒尼替尼的平均IC50值为8.11 μM。选取化合物7e进行进一步的药理学评估,以深入了解其可能的作用机制。在10 μM浓度下,化合物7e分别在4小时和8小时处理后,使caspase 3/7活性增加了2.4倍和1.85倍,并导致细胞周期G1期细胞百分比下降,相应地S期细胞百分比增加。此外,化合物7e使磷酸化酪氨酸(p-Tyr)水平增加了近两倍,其明显的IC50值为3.8 μM。采用改进的乳化-溶剂扩散法制备了负载7e的聚乳酸-羟基乙酸共聚物(PLGA)微球。负载7e的PLGA微球的平均包封效率为85% ± 1.3。同时,负载7e的微球的体外释放曲线以缓慢且持续的方式释放化合物7e长达21天,且释放曲线符合零级动力学。将7e嵌入PLGA微球中提高了其在体外对人类癌细胞系A549的抗增殖活性,经过120小时孵育后,其IC50值小于0.8 μM。